Oren, I heard the call and disagree. I believe he addressed the imbalance of drop outs here. Also, when referring to the ovarian cancer trials, I believe he was referring to the treatment landscape of PARP inhibitors and how that will change the treatment landscape. In rGBM, he discussed the interim analysis being close to studies' end.
Again, you may be right, but my listen to the conference call doesn't support how the control is doing. He mentioned that when patient's go off study they use checkpoints, and we know that's true as well before patient's going on study, they are using checkpoints.
News 
Market Data 
Discover 
